<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation and treatment of subacute and chronic cough in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation and treatment of subacute and chronic cough in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation and treatment of subacute and chronic cough in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven E Weinberger, MD, MACP, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kai Saukkonen, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Barnes, DM, DSc, FRCP, FRS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prolonged cough can be a particularly bothersome symptom that precipitates many outpatient visits to the clinician for treatment. Three categories of cough that are distinguished based upon duration help with the approach to diagnosis and treatment [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute cough, lasting less than three weeks</p><p class="bulletIndent1"><span class="glyph">●</span>Subacute cough, lasting between three and eight weeks</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic cough, lasting more than eight weeks</p><p></p><p>Specific therapy for the most common causes of subacute and chronic cough and nonspecific suppressive therapy for refractory cough will be reviewed here. The causes and complications of subacute and chronic cough are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">INITIAL EVALUATION</span></p><p class="headingAnchor" id="H4177656969"><span class="h2">Algorithmic approach</span><span class="headingEndMark"> — </span>There is general agreement that the initial approach to a patient with subacute or chronic cough should follow a systematic algorithmic or tiered approach to evaluation  (<a class="graphic graphic_algorithm graphicRef67147" href="/z/d/graphic/67147.html" rel="external">algorithm 1</a>) [<a href="#rid1">1-3</a>]. If initial investigations fail to reveal the underlying cause of chronic cough, several physician specialists (including internist or geriatrician, otorhinolaryngologist, pulmonologist, allergist, and/or gastroenterologist) may need to be involved to ensure effective diagnosis and therapy [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H3554412724"><span class="h2">Exclude serious underlying processes</span><span class="headingEndMark"> — </span>The initial evaluation (detailed history and physical examination) should identify any danger signs that may indicate a diagnosis that needs urgent attention [<a href="#rid5">5</a>]. Important danger signs that will need further evaluation with a chest radiograph and possibly laboratory testing and computed tomography (CT) include the following.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fevers, night sweats, or weight loss</strong> raises suspicion for chronic infection (eg, tuberculosis, lung abscess) or rheumatic disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Purulent sputum</strong> warrants evaluation for pulmonary and possibly sinus infection, followed by treatment of identified infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoptysis</strong> can be an indicator of infection (eg, bronchiectasis, lung abscess, tuberculosis), cancer (eg, lung, bronchus, or larynx), rheumatologic diseases, heart failure, or foreign body inhalation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dyspnea</strong> can be a clue to airway obstruction (laryngeal, tracheal, bronchial, bronchiolar) or lung parenchymal disease. Other features such as waxing and waning versus progressively worsening symptoms, particular triggers, associated hoarseness, and focal abnormalities on examination can help focus the investigation. Pulmonary function testing, including pre- and postbronchodilator testing, is important to characterize the potential problem causing both dyspnea and cough.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosuppression</strong> can be a risk factor for infections such as tuberculosis and should prompt a diligent and rapid evaluation for infection.</p><p></p><p class="headingAnchor" id="H3930055797"><span class="h2">Initial steps</span><span class="headingEndMark"> — </span>The most common causes of subacute cough are postinfectious cough and exacerbation of underlying diseases such as asthma, chronic obstructive pulmonary disease (COPD), and upper airway cough syndrome (UACS, commonly referred to as post-nasal drip); the most common causes of chronic cough are asthma, gastroesophageal reflux, UACS due to rhinosinus conditions, nonasthmatic eosinophilic bronchitis, and combinations of these [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical evaluation</strong> – The characteristics of cough should be determined: duration, productive or nonproductive, associated symptoms (eg, rhinorrhea, nasal congestion, sneeze, fever, sputum production, hemoptysis, dyspnea, weight loss, dysphonia, dysphagia, peripheral edema), and prior episodes. Patients should be asked about personal or family history of allergic rhinoconjunctivitis, tobacco use, vaping (eg, electronic cigarettes), occupational exposures, and travel-related exposures.</p><p></p><p class="bulletIndent1">Patients with prolonged cough after pertussis infection often report paroxysmal cough, posttussive vomiting, inspiratory whooping, and absence of fever [<a href="#rid6">6,7</a>]. The choice of further diagnostic tests (culture, polymerase chain reaction, serology) depends upon the duration of cough, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8045.html" rel="external">"Pertussis infection in adolescents and adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/8044.html" rel="external">"Pertussis infection in adolescents and adults: Treatment and prevention"</a>.)</p><p></p><p class="bulletIndent1">Physical examination should make note of nasal congestion, pharyngeal erythema, tonsillar swelling, hoarseness, stridor, wheeze (particularly focal wheeze), crackles, and other adventitious sounds (ie, rub).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tobacco use</strong> – Tobacco smoking is an irritant that can contribute to cough in addition to being a risk factor for chronic bronchitis and lung cancer. A chest CT may be needed to identify cancers missed by a chest radiograph. Smoking cessation should be encouraged. Cough due to cigarette smoking will often improve with smoking cessation, particularly in patients with early COPD. (See  <a class="medical medical_review" href="/z/d/html/16706.html" rel="external">"Benefits and consequences of smoking cessation", section on 'Pulmonary disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest radiograph</strong> – Most adults with a cough &gt;8 weeks in duration should have a chest radiograph. Possible exceptions include patients in whom UACS or asthma seems likely who can initially receive empiric therapy for the suspected diagnosis [<a href="#rid1">1,2</a>]. Chest CT should <strong>not</strong> be obtained routinely for patients with a normal chest examination and chest radiograph but may be required for further evaluation of abnormalities on chest radiograph or potential suspected diagnoses that may be missed on plain radiography (eg, bronchiectasis) [<a href="#rid1">1</a>]. The threshold to obtain a chest CT for chronic cough may be lower in those patients with increased risk for lung cancer, such as heavy smoking history.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary function testing</strong> – Spirometry pre- and postbronchodilator is commonly obtained to evaluate possible asthma or COPD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Review medication list for potential culprit medications</strong> – Patients taking an angiotensin-converting enzyme inhibitor should have a trial of medication discontinuation for at least four weeks before extensive other testing for a cause of chronic cough. Other medications that have been associated with chronic cough include medications that worsen pre-existing gastroesophageal reflux, such as calcium channel blockers and bisphosphonates. (See <a class="local">'Angiotensin-converting enzyme inhibitors'</a> below and  <a class="medical medical_review" href="/z/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults", section on 'ACE inhibitors and other medications'</a>.)</p><p></p><p class="headingAnchor" id="H127993264"><span class="h1">EMPIRIC THERAPY FOR COMMON CAUSES</span><span class="headingEndMark"> — </span>The most common causes of subacute and chronic cough should be addressed in an organized fashion  (<a class="graphic graphic_algorithm graphicRef67147" href="/z/d/graphic/67147.html" rel="external">algorithm 1</a>). Using a sequential, empiric approach to therapy has diagnostic as well as therapeutic utility. It is usually best to follow one avenue of treatment at a time rather than several branches of treatment simultaneously. If there is partial but incomplete resolution of the cough with one line of therapy, then it is reasonable to add therapy for the next most likely diagnostic possibility. (See  <a class="medical medical_review" href="/z/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults", section on 'Causes of chronic cough'</a>.)</p><p>On the other hand, some patients have more than one cause for chronic cough, particularly those seen in a referral clinic. Among such individuals, cough only resolves when all causes are successfully treated at the same time [<a href="#rid8">8</a>]. When more than one etiology is suspected at the time of the initial evaluation and the cough is particularly disabling, empiric treatment or evaluation of likely causes can be pursued simultaneously. Once cough has resolved, treatments can be stopped sequentially, starting with the least likely to have been helpful, observing the patient for any return of cough.</p><p class="headingAnchor" id="H426237382"><span class="h2">Asthma</span><span class="headingEndMark"> — </span>Asthma is the cause of cough in approximately 25 to 30 percent of adult nonsmokers with chronic cough [<a href="#rid9">9-11</a>]. Associated symptoms such as dyspnea and wheeze are common, but cough can be present in isolation (so-called "cough variant asthma").</p><p>Evaluation should include spirometry pre- and postbronchodilator. If spirometry does not demonstrate reversible airflow obstruction, but cough variant asthma is still suspected, it is reasonable to pursue a trial of therapy or proceed to bronchoprovocation challenge (eg, <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">methacholine</a> challenge test). Confirmation that cough is due to asthma requires a beneficial response to therapy for asthma, as patients with asthma can also have cough due to other causes [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults", section on 'Asthma'</a> and  <a class="medical medical_review" href="/z/d/html/525.html" rel="external">"Bronchoprovocation testing"</a>.)</p><p>Therapy for chronic cough as a unique symptom of asthma follows the same general principles as initial therapy for asthma. While robust studies support a stepwise approach to asthma treatment, studies of cough due to asthma are more limited. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled glucocorticoids</strong> – Similar to therapy for mild persistent or moderate asthma, inhaled glucocorticoids (GCs) are the mainstay of therapy for cough due to asthma [<a href="#rid9">9</a>]. We typically start with a low or medium dose of inhaled GC  (<a class="graphic graphic_table graphicRef78011" href="/z/d/graphic/78011.html" rel="external">table 1</a>). If the cough is unimproved after three to four weeks, we increase the dose of inhaled GC or add a leukotriene receptor antagonist.</p><p></p><p class="bulletIndent1">Blood and sputum eosinophil cell counts and fractional exhaled nitric oxide (FE<sub>NO</sub>) measurement have been used in patients with asthma as measures of airway inflammation [<a href="#rid9">9,13-15</a>]. This has led some to suggest that such tests can be used by the clinician in evaluating whether patients with a suboptimal response to therapy for cough variant asthma would benefit from an escalation in their anti-inflammatory asthma treatment [<a href="#rid1">1,16</a>]. Further study of this approach is needed before widespread implementation. (See  <a class="medical medical_review" href="/z/d/html/542.html" rel="external">"Exhaled nitric oxide analysis and applications"</a>.)</p><p></p><p class="bulletIndent1">Inhaled GCs have well-documented benefit in asthma, although studies often do not include cough as an outcome. A systematic review identified four randomized trials (277 participants; study duration 4 to 52 weeks) that demonstrated a reduction in cough score with inhaled GC [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukotriene receptor antagonists (LTRAs)</strong> – The LTRAs are an alternative initial therapy for patients who wish to avoid GCs or for patients who have not responded to GCs and need add-on therapy. The LTRAs improve cough due to asthma compared with placebo based on limited data [<a href="#rid9">9,18</a>]. Addition of an LTRA to inhaled GC has been compared with continuing the inhaled GC in a small, randomized trial of patients with cough variant asthma (22 participants) who were refractory to treatment with inhaled bronchodilators and inhaled GCs; therapy with an LTRA for two or four weeks resulted in decreased cough scores compared with placebo [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/553.html" rel="external">"Antileukotriene agents in the management of asthma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination inhaled GC and long-acting beta-agonist (LABA)</strong> – While combination inhaled GC-LABA has a well-established place in the treatment of asthma, clinical trials to assess the role in chronic cough due to asthma are lacking  (<a class="graphic graphic_table graphicRef68143" href="/z/d/graphic/68143.html" rel="external">table 2</a>) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral glucocorticoids for disabling cough</strong> – For patients who are disabled by their cough, a short (one to two week) course of oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> can be given, generally with excellent results [<a href="#rid17">17,20</a>]. Once the patient has improved, prednisone is discontinued and maintenance therapy with inhaled GCs is continued.</p><p></p><p class="headingAnchor" id="H2789546393"><span class="h2">Nonasthmatic eosinophilic bronchitis</span><span class="headingEndMark"> — </span>Nonasthmatic eosinophilic bronchitis (NAEB) accounts for approximately 10 to 30 percent of patients with chronic cough referred for specialist evaluation [<a href="#rid9">9,21</a>]. Cough may be productive or nonproductive [<a href="#rid22">22</a>]. NAEB should be suspected in patients with atopy, eosinophilic airway inflammation, and when cough improves with inhaled GC, but in the absence of variable airway obstruction or airway hyperresponsiveness [<a href="#rid9">9</a>]. Exposure to potential occupational allergens (eg, isocyanates, flour) may be an additional clue [<a href="#rid9">9,23,24</a>]. The role of measurement of FE<sub>NO</sub> in the diagnosis of NAEB remains unclear [<a href="#rid14">14,25,26</a>]. (See  <a class="medical medical_review" href="/z/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults", section on 'Nonasthmatic eosinophilic bronchitis'</a>.)</p><p>For patients with suspected NAEB, we suggest treatment with inhaled GCs based on observational data and guideline recommendations [<a href="#rid9">9,27,28</a>]. In a systematic review, three randomized trials (56 participants) found improvement in the cough visual analog scale or cough frequency score with inhaled GC compared with placebo [<a href="#rid9">9,29</a>]. Severity of cough and sensitivity to capsaicin-induced cough both improved. The optimal dose and duration of therapy have not been determined. We typically start with a low-to-medium dose inhaled GC, such as <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> 180 to 360 mcg or <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">fluticasone</a> 44 to 110 mcg twice a day. Limited data support continuing inhaled GC for at least two months to reduce the risk of relapse [<a href="#rid29">29</a>].</p><p>Small randomized, open-label trials have examined addition of <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> in NAEB for patients with insufficient improvement in cough with low- or medium-dose inhaled GC [<a href="#rid9">9,30,31</a>]. Addition of montelukast improved cough relative to continuing <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> 400 mcg/day [<a href="#rid31">31</a>] and had a similar improvement in cough compared with doubling the dose of budesonide from 400 mcg/day to 800 mcg/day [<a href="#rid30">30</a>].</p><p>Rarely, oral GCs are needed for refractory symptoms. When an inciting agent (eg, inhaled or occupational allergen) is identified, further exposure should be avoided [<a href="#rid9">9,23,24</a>].</p><p>NAEB usually has a benign course and resolves with inhaled GC. A subgroup of patients will have relapses, and among these some will develop small airways dysfunction.</p><p>Evidence in favor of the use of inhaled corticosteroids in patients with chronic cough and without asthma includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review (eight studies, 570 participants), inhaled GC treatment led to a significant reduction in cough score, but the heterogeneity of the studies precluded a meta-analysis [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial, 44 patients with chronic cough (average duration 20 weeks) were treated with high-dose <a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">beclomethasone</a> (1500 mcg/day), while 20 received placebo [<a href="#rid33">33</a>]. After two weeks, 82 percent of the beclomethasone group and 12 percent of the placebo group had complete resolution of cough. Response to beclomethasone did not correlate with atopy or bronchial hyperresponsiveness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one study, for example, there was a suggestion that more patients with chronic cough responded to inhaled GCs (<a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">beclomethasone</a> 2000 mcg/day) than to placebo, although overall mean daily cough scores were not significantly different in the two groups [<a href="#rid34">34</a>].</p><p></p><p>A potential reason for variable responses to inhaled GCs may be related to the dose used. One study that showed no benefit to inhaled GCs in patients with chronic nonasthmatic cough used a low-dose of inhaled GC (<a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">beclomethasone</a> 400 mcg/day) [<a href="#rid35">35</a>]. Another potential reason for inconsistent results may reflect variable numbers of patients with nonasthmatic eosinophilic bronchitis in the study population.</p><p class="headingAnchor" id="H4"><span class="h2">Upper airway cough syndrome</span><span class="headingEndMark"> — </span>Upper airway cough syndrome (UACS; previously known as postnasal drip syndrome but revised to include all upper airway abnormalities associated with cough) has a number of different etiologies, including allergic, nonallergic, and vasomotor rhinitis; acute nasopharyngitis; and sinusitis [<a href="#rid36">36</a>]. However, the mechanism by which UACS would cause chronic cough remains unclear. One possibility is that UACS acts as a trigger for cough in patients with cough hypersensitivity [<a href="#rid1">1</a>].</p><p>Practice parameters for the diagnosis and management of rhinitis have been published [<a href="#rid37">37</a>]. These guidelines describe high-quality evidence that intranasal GCs are the most effective therapy for symptoms of allergic rhinitis  (<a class="graphic graphic_table graphicRef55833" href="/z/d/graphic/55833.html" rel="external">table 3</a>). In addition, intranasal GCs are effective for several types of nonallergic rhinitis, including nonallergic rhinitis with eosinophilia and vasomotor rhinitis. For patients with cough due to allergic rhinitis, intranasal GCs are generally effective in reducing cough within the first few days but may take up to two weeks to achieve maximal effect. If the patient responds, therapy is continued until pollen or ambient allergen counts are low and/or exposure to possible inciting antigens is minimized [<a href="#rid38">38</a>]. When an environmental precipitant for allergic rhinitis can be identified, exposure to this precipitant should be eliminated if possible. (See  <a class="medical medical_review" href="/z/d/html/7525.html" rel="external">"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis"</a>.)</p><p>Only a few trials have evaluated the effect of oral nonsedating antihistamines on cough associated with seasonal allergic rhinitis, asthma, or atopy, and results are mixed [<a href="#rid39">39</a>]. Additional therapies for allergic and nonallergic rhinitis and chronic rhinosinusitis are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis"</a> and  <a class="medical medical_review" href="/z/d/html/7532.html" rel="external">"Chronic nonallergic rhinitis"</a> and  <a class="medical medical_review" href="/z/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/121194.html" rel="external">"Chronic rhinosinusitis without nasal polyposis: Management and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a>.)</p><p>For patients with suspected nonallergic UACS, we suggest a trial of therapy with intranasal administration of one or more of the following: <a class="drug drug_general" data-topicid="8798" href="/z/d/drug information/8798.html" rel="external">azelastine</a>, glucocorticoid, or <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> [<a href="#rid37">37</a>]. However, azelastine may cause somnolence even with intranasal use. Intranasal ipratropium significantly reduces the rhinorrhea associated with perennial nonallergic rhinitis and has few side effects [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/7532.html" rel="external">"Chronic nonallergic rhinitis", section on 'Efficacy of antihistamine sprays'</a> and  <a class="medical medical_review" href="/z/d/html/7532.html" rel="external">"Chronic nonallergic rhinitis", section on 'Prominent rhinorrhea without other symptoms'</a>.)</p><p>Lack of improvement in cough after one to two weeks of empiric therapy for UACS is evidence that UACS due to allergic or nonallergic rhinitis is not the cause of the cough. However, in the presence of nasal symptoms or signs, a sinus CT scan could be performed before completely excluding the possibility of UACS as a cause of cough.</p><p>The four cardinal symptoms of chronic rhinosinusitis are anterior and/or posterior nasal mucopurulent drainage, nasal obstruction/nasal blockage/congestion, facial pain and/or fullness, and reduced or absent sense of smell. A sinus CT scan or nasal endoscopy is needed to confirm the diagnosis. The treatment of chronic rhinosinusitis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121194.html" rel="external">"Chronic rhinosinusitis without nasal polyposis: Management and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Gastroesophageal reflux</span><span class="headingEndMark"> — </span>Cough due to gastroesophageal reflux disease (GERD) generally responds to a regimen that includes lifestyle modifications and acid suppression medication [<a href="#rid12">12,41-43</a>]:</p><p class="headingAnchor" id="H8"><span class="h3">Lifestyle modifications</span><span class="headingEndMark"> — </span>The evidence in favor of lifestyle modifications to reduce or prevent GERD and thereby treat cough is limited [<a href="#rid12">12,41</a>]. The following interventions are based on the lifestyle modifications that are suggested for the routine management of GERD:</p><p class="bulletIndent1"><span class="glyph">●</span>Weight loss for patients who are overweight</p><p class="bulletIndent1"><span class="glyph">●</span>Elevation of the head of the bed (eg, place six- to eight-inch blocks under the legs at the head of the bed or a Styrofoam wedge under the mattress)</p><p class="bulletIndent1"><span class="glyph">●</span>Cessation of smoking</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of reflux-inducing foods (eg, fatty foods, chocolate, alcohol, caffeinated beverages)</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of very acidic beverages (eg, carbonated beverages, red wine, orange juice)</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of meals for two to three hours before lying down (except for medications)</p><p></p><p>Lifestyle modification in the management of GERD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">"Medical management of gastroesophageal reflux disease in adults", section on 'Lifestyle and dietary modification'</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Acid-suppression medication</span><span class="headingEndMark"> — </span>For patients with chronic cough and symptoms of reflux (eg, heartburn, regurgitation), we suggest a trial of acid suppression medication combined with lifestyle modifications [<a href="#rid12">12</a>]. However, regimens proven effective in the management of GERD may not necessarily be the optimum regimens for cough due to GERD. A meta-analysis of randomized trials of medical GERD interventions for cough showed that while such therapy indeed has some effect in adults, the frequency is less universal than often suggested in consensus guidelines [<a href="#rid44">44</a>]. A possible explanation for failure to improve despite acid suppression is that of nonacidic reflux [<a href="#rid12">12</a>].</p><p>We suggest using an empiric trial of a proton pump inhibitor (PPI) at a moderate dose (eg, <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">omeprazole</a> 40 mg once daily in the morning). This is based on the evidence that therapy with a PPI is more effective than H<sub>2</sub> antagonist treatment [<a href="#rid45">45</a>]. In addition, as it may take up to eight weeks, and sometimes several months, to yield optimal improvement in cough, it seems reasonable to start with the more effective choice [<a href="#rid12">12,41</a>].</p><p>For patients whose cough does not improve after one to two months of empiric therapy, we proceed to 24-hour esophageal pH probe monitoring. Results that suggest cough due to GERD include an abnormal amount of time with an esophageal pH less than four and cough occurring within a few minutes of reflux events. Multichannel intraluminal impedance (MII) monitoring, which is increasingly available, may help identify patients with cough from nonacidic reflux. Due to its higher availability in some practice locations, a barium esophagram may be a helpful alternative in selected patients, especially if there is concern for hiatal hernia, esophageal stricture, or esophageal dysmotility. (See  <a class="medical medical_review" href="/z/d/html/2265.html" rel="external">"Clinical manifestations and diagnosis of gastroesophageal reflux in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2248.html" rel="external">"Esophageal multichannel intraluminal impedance testing"</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Other therapies</span><span class="headingEndMark"> — </span>Other therapies are less well validated:</p><p class="bulletIndent1"><span class="glyph">●</span>Prokinetic therapy – The addition of prokinetic therapy such as <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> may be beneficial in patients with nonacidic reflux or may add to the effectiveness of acid suppression therapy in cough due to acidic reflux. However, supportive data are weak, and patients placed on metoclopramide should be followed for the possible development of extrapyramidal side effects (eg, rigidity, bradykinesia, tremor, and restlessness).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antireflux surgery – The role of antireflux surgery to relieve extraesophageal symptoms related to GERD is unclear [<a href="#rid46">46-48</a>]. We reserve laparoscopic or open Nissen fundoplication for the small number of patients with chronic cough who have objectively documented gastroesophageal or laryngopharyngeal reflux disease that is refractory to medical measures. In a meta-analysis of 25 studies, a variable proportion of patients (15 to 95 percent) experienced improvement in extraesophageal symptoms (including but not limited to cough) after surgical fundoplication [<a href="#rid48">48</a>]. The studies were all nonrandomized and used variable selection criteria. In a subsequent observational study of 16 patients with nonacid reflux by MII, antireflux surgical procedures resulted in cough resolution in 13 and cough improvement in 3 patients [<a href="#rid47">47</a>]. A meta-analysis of the results of antireflux surgery in GERD with respiratory symptoms found that different surgical techniques or a combination of them led to cough relief in 83.4 percent of patients [<a href="#rid49">49</a>]. Nissen fundoplication has been reported to result in complete resolution of chronic cough in approximately three-fourths of patients [<a href="#rid50">50,51</a>]. (See  <a class="medical medical_review" href="/z/d/html/2258.html" rel="external">"Medical management of gastroesophageal reflux disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2278.html" rel="external">"Surgical treatment of gastroesophageal reflux in adults"</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Persistent cough after upper respiratory tract infection</span><span class="headingEndMark"> — </span>Cough following an upper respiratory tract infection may be due to postnasal drip or a direct effect of the viral infection to increase bronchial reactivity or cough receptor sensitivity. For patients in whom postnasal drip (ie, UACS) seems to be contributing to the prolonged cough following a viral upper respiratory tract infection, the treatment follows that for nonallergic UACS, as described above [<a href="#rid52">52</a>]. (See <a class="local">'Upper airway cough syndrome'</a> above.)</p><p>First-generation antihistamines (eg, brompheniramine, <a class="drug drug_general" data-topicid="8860" href="/z/d/drug information/8860.html" rel="external">chlorpheniramine</a>, <a class="drug drug_general" data-topicid="9274" href="/z/d/drug information/9274.html" rel="external">clemastine</a>, <a class="drug drug_general" data-topicid="8796" href="/z/d/drug information/8796.html" rel="external">doxylamine</a>), although more sedating, have stronger anticholinergic effects than second-generation agents (eg, <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">cetirizine</a>, <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">loratadine</a>, <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">fexofenadine</a>) and therefore may be superior for treating cough secondary to the common cold [<a href="#rid36">36,52-55</a>].</p><p>Some patients with postviral cough without UACS have transient airway hyperreactivity that is associated with a positive <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">methacholine</a> challenge test in research studies [<a href="#rid20">20</a>]. <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">Albuterol</a> may be of benefit in such patients, although data are limited. Alternatively, in patients with postviral cough who have no evidence of airway hyperreactivity, inhaled <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> has been reported to produce improvement in the cough [<a href="#rid56">56</a>]. Among 14 such patients in one report, 12 had clinical improvement with administration of 320 mcg of inhaled ipratropium, and of these, five had complete resolution of cough [<a href="#rid57">57</a>].</p><p>Infection due to <em>Bordetella pertussis</em> (whooping cough) may be responsible for approximately 20 percent of cases of prolonged cough in adolescents and adults. It is therefore important to consider this diagnosis in the patient with an apparent postinfectious cough, especially if cough is associated with an inspiratory whooping sound or posttussive vomiting [<a href="#rid6">6,56,58</a>]. A systematic review did not find evidence that antihistamines (<a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>) or beta adrenergic agonists alleviated cough due to pertussis [<a href="#rid59">59</a>]. For the majority of patients, antibiotic therapy does not reduce the duration of symptoms but may be appropriate in certain patients to reduce disease transmission, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8044.html" rel="external">"Pertussis infection in adolescents and adults: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Angiotensin-converting enzyme inhibitors</span><span class="headingEndMark"> — </span>For patients who develop a chronic cough during treatment with an angiotensin-converting enzyme (ACE) inhibitor, the treatment of choice is withdrawal of the ACE inhibitor [<a href="#rid1">1</a>]. The cough will typically resolve within one to four weeks after stopping the ACE inhibitor but occasionally will last up to three months [<a href="#rid60">60</a>]. Reinitiation of the same or another ACE inhibitor usually leads to recurrent cough. (See  <a class="medical medical_review" href="/z/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers", section on 'Cough'</a>.)</p><p>Angiotensin II receptor antagonists are alternative antihypertensive agents that act via a related mechanism but do not affect kinin metabolism. They are not associated with an increased incidence of cough, even in patients who had previously had an ACE inhibitor-induced cough [<a href="#rid1">1,60,61</a>]. Angiotensin II receptor antagonists also do not increase cough or bronchial hyperresponsiveness in symptomatic asthmatics [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H13"><span class="h1">UNEXPLAINED CHRONIC COUGH</span></p><p class="headingAnchor" id="H3176443918"><span class="h2">General approach</span><span class="headingEndMark"> — </span>A portion of patients experience a cough that persists for more than eight weeks and is not adequately treated despite systematic assessment and empiric therapies  (<a class="graphic graphic_algorithm graphicRef67147" href="/z/d/graphic/67147.html" rel="external">algorithm 1</a>) [<a href="#rid63">63</a>]. (See <a class="local">'Empiric therapy for common causes'</a> above.)</p><p>For patients whose cough remains unexplained despite thorough evaluation and empiric trials of specific therapies, the next step includes nonpharmacologic therapy such as speech therapy and treatment with nonspecific antitussive agents.</p><p>Several studies have noted a substantial minority of patients who do not respond or respond inadequately to specific interventions and treatments [<a href="#rid16">16,64,65</a>]. Rarely, these patients have another underlying airway, parenchymal disease, or extrapulmonary vagal irritation as the cause of their cough; a careful history, physical examination, and chest imaging should be performed to ensure these causes are not overlooked. (See <a class="local">'Exclude serious underlying processes'</a> above and  <a class="medical medical_review" href="/z/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults", section on 'Causes of acute cough'</a>.)</p><p>More often, however, they have what may be called "unexplained chronic cough," "chronic idiopathic cough," "neurogenic cough," or "cough hypersensitivity syndrome" [<a href="#rid66">66</a>]. This disorder may in part be due to an abnormally sensitive cough reflex, perhaps in the form of heightened sensory nerve receptor sensitivity due to alterations in receptor ion channels, such as transient receptor potential vanilloid 1 or transient receptor potential ankyrin 1 [<a href="#rid66">66-70</a>]. (See  <a class="medical medical_review" href="/z/d/html/529.html" rel="external">"Neuronal control of the airways"</a>.)</p><p>Research is underway to develop cough receptor antagonists, but until such specific receptor antagonists are available, the nonspecific cough remedies are reasonable choices for the management of disabling chronic cough that has not responded to specific therapy [<a href="#rid71">71-74</a>]. (See <a class="local">'Investigational agents'</a> below.)</p><p class="headingAnchor" id="H403342939"><span class="h2">Ipratropium</span><span class="headingEndMark"> — </span>The muscarinic antagonist (anticholinergic agent) <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> has been proposed to have at least two potential mechanisms by which it may alleviate cough when orally inhaled [<a href="#rid73">73</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Blocking the efferent limb of the cough reflex</p><p class="bulletIndent1"><span class="glyph">●</span>Decreasing stimulation of cough receptors by alteration of mucociliary factors</p><p></p><p>As mentioned above, a beneficial effect of <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> has been noted in a small group of patients with persistent cough following upper respiratory tract infection [<a href="#rid57">57</a>], although this observation has not been replicated [<a href="#rid63">63</a>]. The usual dose of ipratropium is two inhalations by metered dose inhaler four times a day. (See <a class="local">'Persistent cough after upper respiratory tract infection'</a> above.)</p><p class="headingAnchor" id="H3897522581"><span class="h2">Nonpharmacologic interventions</span><span class="headingEndMark"> — </span>Modalities such as speech therapy, breathing exercises, cough suppression techniques, and patient counseling have been tried in the management of chronic cough [<a href="#rid75">75-78</a>]. A systematic review reported that studies of such interventions showed improved cough severity and frequency, but few of them used validated cough measurement tools [<a href="#rid77">77</a>]. While the robustness of these findings is limited, in accordance with guidelines, we suggest a therapeutic trial of multimodality speech therapy in motivated patients with unexplained chronic cough who have not responded to an algorithmic approach, such as the one described above  (<a class="graphic graphic_algorithm graphicRef67147" href="/z/d/graphic/67147.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H2816130049"><span class="h2">Nonspecific antitussive agents</span><span class="headingEndMark"> — </span>The role of nonspecific antitussive agents in the management of chronic cough remains unclear. Many patients have already tried home remedies such as throat lozenges, hot tea, and honey without success and are eager for symptomatic relief while the evaluation proceeds. We typically try <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> or <a class="drug drug_general" data-topicid="9098" href="/z/d/drug information/9098.html" rel="external">benzonatate</a> as nonspecific agents that are helpful for some patients with unexplained chronic cough before using more sedating agents. Definitive evidence of benefit is lacking for these nonspecific agents.</p><p class="headingAnchor" id="H1752386866"><span class="h3">Dextromethorphan</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">Dextromethorphan</a> is probably the most common nonopioid agent used for cough. It decreases the sensitivity of cough receptors and is an N-methyl-D-aspartate receptor antagonist. We suggest a therapeutic trial of this agent in patients with chronic refractory cough whether due to an unknown mechanism or a cause such as lung cancer that is not otherwise remediable [<a href="#rid1">1</a>]. The usual dose is extended release 60 mg orally twice a day. Dextromethorphan is also available as a component of over-the-counter cough syrups.</p><p>In a systematic review that analyzed studies of <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> versus placebo, the quality of the studies was generally felt to be fair to poor [<a href="#rid79">79</a>]. Nonetheless, dextromethorphan was found to modestly decrease cough severity (five studies) and frequency (two studies).</p><p>Studies that have compared <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a> and <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> have shown variable results, but the number of subjects in each study is small [<a href="#rid79">79</a>]. (See <a class="local">'Codeine'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>In a crossover study of 16 patients with chronic, stable cough, <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a> (20 mg) and <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> (20 mg) were equally effective in reducing cough frequency [<a href="#rid80">80</a>]. However, because cough intensity was lowered more by dextromethorphan than by codeine, the majority of patients preferred the use of dextromethorphan.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An observational study of eight patients demonstrated equal antitussive effects from <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a> 30 mg and <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> 60 mg, each of which was superior to dextromethorphan 30 mg and to placebo [<a href="#rid81">81</a>].</p><p></p><p class="headingAnchor" id="H2590107089"><span class="h3">Benzonatate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9098" href="/z/d/drug information/9098.html" rel="external">Benzonatate</a> is a peripherally acting antitussive agent that presumably acts by anesthetizing stretch receptors in the lungs and pleura. For patients with mild chronic cough, a trial of benzonatate, usually in addition to or after a failed trial of <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a>, is reasonable, although often of limited benefit. The usual dose is 100 to 200 mg orally three times a day. One report showed that a combination of 200 mg of benzonatate and 600 mg of <a class="drug drug_general" data-topicid="8503" href="/z/d/drug information/8503.html" rel="external">guaifenesin</a> significantly suppressed capsaicin-induced cough compared with guaifenesin alone [<a href="#rid82">82</a>].</p><p>There are case reports of effective use of <a class="drug drug_general" data-topicid="9098" href="/z/d/drug information/9098.html" rel="external">benzonatate</a> in the palliative treatment of cough in advanced cancer [<a href="#rid83">83</a>]. It may be tried as an adjunctive treatment to narcotics in such cases.</p><p>Accidental ingestion of <a class="drug drug_general" data-topicid="9098" href="/z/d/drug information/9098.html" rel="external">benzonatate</a> and fatal overdoses have been reported in children &lt;10 years of age [<a href="#rid84">84</a>]. Signs and symptoms of overdose (restlessness, tremors, convulsion, coma, cardiac arrest) may occur within 15 to 20 minutes after ingestion.</p><p class="headingAnchor" id="H1729101192"><span class="h3">Guaifenesin</span><span class="headingEndMark"> — </span>Proposed mechanisms by which <a class="drug drug_general" data-topicid="8503" href="/z/d/drug information/8503.html" rel="external">guaifenesin</a> might reduce cough include decreasing the viscosity of airway mucus and inhibiting cough reflex sensitivity in patients with transiently hypersensitive cough receptors. While individual patients report benefit, formal study is lacking. The dose of extended-release guaifenesin is 600 to 1200 mg every 12 hours as needed. Possible adverse side effects include nausea, abdominal pain, and dizziness.</p><p class="headingAnchor" id="H1057057164"><span class="h3">Nebulized lidocaine</span><span class="headingEndMark"> — </span>Nebulized <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> may reduce the frequency of cough, but its use is generally limited by adverse effects, particularly unpleasant taste and symptomatic aspiration.</p><p>In an observational study, nebulized <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> (3 mL of 4 percent lidocaine [120 mg]) was prescribed two or three times daily to patients with chronic cough, with the option to increase the dose (to 5 mL [200 mg]) if numbness of the throat lasted less than 20 minutes [<a href="#rid85">85</a>]. Among 99 patients who responded to a follow-up questionnaire, cough severity scores decreased, generally by two weeks. Only 34 percent of patients reported being satisfied with the treatment and less than 30 percent chose to continue it beyond three months. Adverse events, such as unpleasant taste, throat irritation, and choking on water or food, were reported by 43 percent.</p><p class="headingAnchor" id="H1618325537"><span class="h2">Gabapentin and pregabalin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, gamma aminobutyric acid analogs that bind to the voltage-gated calcium channels and inhibit neurotransmitter release, are thought to ameliorate chronic neuropathic pain via a central mechanism [<a href="#rid5">5,86</a>]. It is hypothesized that these agents may also act to reduce chronic cough via a central mechanism. Neither medication is approved for use in chronic cough, although gabapentin is recommended for unexplained chronic cough in the American College of Chest Physicians (ACCP) guidelines [<a href="#rid63">63</a>]. The supportive data for the use of pregabalin were published after the ACCP guidelines were prepared. These agents may be helpful in patients with cough refractory to nonspecific antitussive therapy, particularly those who wish to avoid or do not tolerate opioid agents.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gabapentin</strong> – To reduce adverse effects of sedation and dizziness, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> is initiated at a low dose (300 mg once a day) with gradual increases until cough relief, dose-limiting adverse effects, or a dose of 1800 mg a day in two divided doses is achieved [<a href="#rid63">63</a>]. For patients who have significant somnolence with 300 mg capsules, the 100 mg capsule may provide benefit without somnolence. There is a liquid formulation, as well, for the occasional patient who would benefit from even lower doses. Other than somnolence, adverse effects may include diarrhea, nausea, emotional lability, nystagmus, tremor, weakness, and peripheral edema. After six months, therapy should be reassessed to determine whether gabapentin is still needed to control cough [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1">The evidence in favor of using <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> for chronic cough includes a randomized trial in which 62 patients with refractory chronic cough were assigned to receive either gabapentin (in doses up to 1800 mg daily) or placebo for 10 weeks [<a href="#rid87">87</a>]. Cough-specific quality-of-life measures were significantly improved in the gabapentin group (between group difference in Leicester Cough Questionnaire during treatment period 1.80, 95% CI 0.56-3.04; number needed to treat 4). Additionally, cough appeared to worsen upon cessation of the gabapentin. Side effects, chiefly nausea and fatigue, occurred in over 30 percent of those receiving gabapentin and were often managed by dose reduction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregabalin</strong> – As with <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> is initiated at a low dose and gradually increased over a week to 300 mg/day to minimize sedation and dizziness.</p><p></p><p class="bulletIndent1">The evidence for using <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> in chronic cough comes from a randomized trial in which 40 adults with chronic refractory cough (&gt;8 weeks duration) were assigned to take pregabalin 300 mg daily with speech pathology treatment (SPT) or placebo with SPT for 14 weeks [<a href="#rid75">75</a>]. Baseline cough frequency was 24 coughs/hour in both groups; spirometry was normal. Both groups experienced a reduction in cough severity by visual analog scale (VAS), cough frequency, and Leicester Cough Questionnaire quality of life (QOL). The pregabalin group experienced greater improvement in VAS (mean difference 25.1, 95% CI 10.6-39.6) and in QOL (mean difference 3.5, 95% CI 1.1-5.8). Adverse effects in the pregabalin group included dizziness in 45 percent and cognitive changes in 30 percent, although these did not lead to discontinuation of the study drug. Four weeks after withdrawal of study medication, there was no deterioration in symptom control.</p><p></p><p class="headingAnchor" id="H3159090021"><span class="h2">Opiates</span><span class="headingEndMark"> — </span>Opiates are thought to suppress cough via an action on the central cough center and may have efficacy in patients with chronic refractory cough whether due to an unknown mechanism or a cause such as lung cancer that does not respond to a trial of typical nonspecific antitussive agents (eg, <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> and <a class="drug drug_general" data-topicid="9098" href="/z/d/drug information/9098.html" rel="external">benzonatate</a>) [<a href="#rid1">1</a>]. Our authors typically prefer other methods, reserving opiate therapies for occasional time-limited use or as palliative therapy for advanced interstitial lung disease or pulmonary malignancy.</p><p>For patients in whom nonopiate options are ineffective, and they are willing to accept the risk of opiate-related adverse effects, a limited trial (typically four to six weeks) of long-acting <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> or <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a> may be helpful by allowing mucosal healing from repetitive cough injury. We discontinue therapy promptly in those who do not have symptomatic improvement over the first two weeks. Because of concern about opiate dependence, longer-term use should be limited to patients for whom palliation of symptoms due to serious disease (eg, intrathoracic malignancy) outweighs the risk of opiate dependence. (See  <a class="medical medical_review" href="/z/d/html/83242.html" rel="external">"Palliative care: Overview of cough, stridor, and hemoptysis in adults", section on 'Symptom-directed treatment'</a>.)</p><p class="headingAnchor" id="H394867877"><span class="h3">Morphine</span><span class="headingEndMark"> — </span>Sustained-release <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> reduced cough within a week in approximately half of patients with chronic cough in one clinical trial of patients with refractory chronic cough [<a href="#rid1">1</a>]. Low doses of long-acting formulations are preferred to allow a steady antitussive effect. We begin with the lowest extended-release or sustained-release dose available (typically 10 to 15 mg once or twice daily, depending on preparation and availability), with cautious escalation to no more than 15 mg twice daily for those who tolerate the lower dose and have minimal relief after the first week. Patients should be warned about potential somnolence and constipation. (See  <a class="medical medical_review" href="/z/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain"</a>.)</p><p>In a double-blind crossover trial, 27 patients who had a persistent cough of greater than three months duration and had failed specific treatment were randomly assigned to receive slow-release <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> (5 mg twice daily) or placebo for four weeks [<a href="#rid88">88</a>]. Morphine reduced daily cough severity scores (Leicester Cough Questionnaire) by 40 percent, although the cough reflex was unaltered. Among those patients who did not respond to 5 mg twice daily, improvement was detected when the dose was increased to 10 mg twice daily.</p><p class="headingAnchor" id="H3049402021"><span class="h3">Codeine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">Codeine</a>, a pro-drug metabolized to <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> in the liver, is the traditional opiate used for cough, but morphine likely has a less variable response and is now preferred by some guidelines [<a href="#rid1">1</a>]. Despite widespread use, evidence regarding codeine’s efficacy for chronic cough is limited, with variable patient responses observed [<a href="#rid79">79-81,89-91</a>]. When prescribing codeine, the usual initial dose is 30 mg every four to six hours as needed and increased to 60 mg if the lower dose is insufficient. We caution patients about potential adverse effects such as somnolence and constipation. (See  <a class="medical medical_review" href="/z/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain"</a>.)</p><p>In a systematic review, <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a> was more effective than placebo in reducing the severity and frequency of cough, although the quality of the available studies was judged to be fair or poor [<a href="#rid79">79</a>]. In a randomized trial, 64 subjects with subacute cough were randomly assigned to receive codeine (30 mg twice daily), an investigational antitussive, or placebo [<a href="#rid90">90</a>]. Codeine reduced cough counts relative to placebo, but the effect was not statistically significant. However, the dose of codeine was low, as the usual dosing in adults is 30 to 60 mg every four hours. In a brief intervention study, 21 patients with cough due to chronic bronchitis were randomly assigned to codeine 60 mg twice a day or placebo for a one-day study [<a href="#rid89">89</a>]. No significant difference was noted in cough counts or subjective cough scores between the study groups, although the study size was small and the dose of codeine low.</p><p class="headingAnchor" id="H729443886"><span class="h2">Investigational agents</span></p><p>Work is underway to identify treatments for patients who have a chronic cough without a remediable cause despite careful investigation  (<a class="graphic graphic_algorithm graphicRef67147" href="/z/d/graphic/67147.html" rel="external">algorithm 1</a>) and empiric trials of therapy.</p><p class="headingAnchor" id="H1659729660"><span class="h3">P2X3 antagonists</span><span class="headingEndMark"> — </span>Based on laboratory studies, increased sensitivity of P2X3 receptors on the airway sensory nerve fibers (eg, vagal afferent C fibers) is a potential cause of refractory cough [<a href="#rid92">92</a>]. Early studies of some of these agents showed efficacy but high rates of taste disturbance [<a href="#rid93">93,94</a>]. Multiple P2X3 antagonists are undergoing development as potential therapies for chronic cough [<a href="#rid95">95,96</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gefapixant</strong> – Gefapixant is the most well-studied P2X3 antagonist. In a meta-analysis of six trials including 2472 patients, gefapixant 45 mg twice daily reduced 24-hour cough frequency to a greater extent than placebo (66 versus 50 percent reduction [mean difference 16 percent, 95% CI 9.4-22] [<a href="#rid97">97</a>], accompanied by a modest improvement in cough-specific quality of life. Nearly one-third of patients experienced taste-related adverse events, 30 percent of which were serious enough to lead to discontinuation. These data reflect moderate certainty that gefapixant yields improvement in cough outcomes despite the robust placebo effect seen in these trials. Unfortunately, such improvements come with a significant risk of serious taste disturbance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sivopixant</strong> – Sivopixant is a P2X3 antagonist designed to be more selective for P2X3 receptors to avoid taste disturbance side effects. In a cross-over trial of 30 subjects with refractory cough, cough counts decreased by 53 percent with sivopixant compared with 31 percent with placebo (a 31 percent relative difference) [<a href="#rid98">98</a>]. Mild taste disturbance occurred in only two patients (6.5 percent).</p><p></p><p class="headingAnchor" id="H2999906154"><span class="h2">Therapies without benefit</span></p><p class="headingAnchor" id="H3930361202"><span class="h3">Macrolide antibiotics</span><span class="headingEndMark"> — </span>Patients with chronic cough tend to have increased levels of neutrophils in their induced sputum. This led to the hypothesis that macrolide antibiotics, which have antineutrophil effects independent of antimicrobial effects, might be efficacious in treating chronic cough. However, trials with <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> and <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> have not demonstrated benefit in cough frequency or severity [<a href="#rid99">99,100</a>].</p><p class="headingAnchor" id="H3329307005"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>During vigorous coughing, intrathoracic pressures may reach 300 mmHg and expiratory velocities approach 500 miles per hour [<a href="#rid101">101</a>]. While these pressures and velocities are responsible for the beneficial effects of cough on mucus clearance, they are also responsible for many of the complications of cough, including exhaustion, self-consciousness, insomnia, headache, dizziness, musculoskeletal pain, hoarseness, excessive perspiration, urinary incontinence, and concern that "something is wrong"  (<a class="graphic graphic_table graphicRef63151" href="/z/d/graphic/63151.html" rel="external">table 4</a>) [<a href="#rid102">102,103</a>]. Cough-induced rib fractures are another painful and potentially serious complication of chronic cough. Fractures often involve multiple ribs, particularly ribs five through seven. Females with decreased bone density are at the greatest risk of this complication; however, fractures can occur in patients with normal bone density as well [<a href="#rid104">104</a>]. Paroxysmal or violent coughing, such as that in patients with pertussis or tracheomalacia, may even induce syncope.</p><p class="headingAnchor" id="H1947964826"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115278.html" rel="external">"Society guideline links: Subacute and chronic cough in adults"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16896.html" rel="external">"Patient education: Cough in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/4644.html" rel="external">"Patient education: Chronic cough in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Excluding serious underlying processes</strong> – The initial evaluation (detailed history and physical examination) should identify any danger signs (eg, fever, night sweats, purulent sputum, dyspnea, hemoptysis) that may indicate a diagnosis that needs urgent attention. (See <a class="local">'Exclude serious underlying processes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – The characteristics of cough should be determined: duration, productive or nonproductive, associated symptoms, and prior episodes. Particular attention should be paid to a postinfectious etiology and cough related to tobacco use. In adult patients whose cough has lasted more than eight weeks, a chest radiograph is typically performed as part of the initial evaluation to rule out a potential etiology that would require additional evaluation or focused treatment. (See  <a class="medical medical_review" href="/z/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults", section on 'Lung cancer'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic trial of therapy for common causes</strong> – The best approach to the evaluation of chronic cough (present for more than eight weeks) is to use a systematic combination of empiric therapy and objective testing  (<a class="graphic graphic_algorithm graphicRef67147" href="/z/d/graphic/67147.html" rel="external">algorithm 1</a>). Therapy aimed at a particular etiology should be selected based on clues from the initial evaluation. (See <a class="local">'Empiric therapy for common causes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Asthma</strong> – When asthma is the suspected cause, spirometry pre- and postbronchodilator should be performed. In patients with subacute or chronic cough due to suspected asthma, we recommend regular use of an inhaled glucocorticoid (GC) and as-needed use of an inhaled bronchodilator or combined inhaled GC-formoterol, rather than use of an inhaled bronchodilator alone (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Combination therapy with a leukotriene receptor antagonist and an as-needed, short-acting inhaled bronchodilator is a reasonable alternative. (See <a class="local">'Asthma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonasthmatic eosinophilic bronchitis (NAEB)</strong> – NAEB accounts for approximately 10 to 30 percent of patients with chronic cough referred for specialist evaluation. NAEB should be suspected in patients with atopy, eosinophilic airway inflammation, and potential exposure to occupational allergens but is often diagnosed empirically based on improvement with the use of inhaled glucocorticoids in the absence of airway obstruction or bronchodilator responsiveness. For patients undergoing a treatment trial for suspected NAEB, we suggest the use of low- to medium-dose inhaled glucocorticoids rather than high-dose inhaled glucocorticoids or systemic therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A partial response suggests potential benefit from a trial of dose escalation or add-on leukotriene modifiers. We continue inhaled glucocorticoids for at least two months following improvement in symptoms to reduce the risk of relapse.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Upper airway cough syndrome (UACS)</strong> – In patients with UACS who have a personal or family history suggestive of atopy, we recommend treatment with an intranasal GC, rather than an oral antihistamine (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Combination therapy with an intranasal GC and an oral antihistamine is an acceptable alternative, particularly in a patient with severe symptoms. (See <a class="local">'Upper airway cough syndrome'</a> above and  <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis"</a>.)</p><p></p><p class="bulletIndent2">For patients with suspected nonallergic UACS, we suggest a trial of therapy with intranasal administration of one or more of the following: <a class="drug drug_general" data-topicid="8798" href="/z/d/drug information/8798.html" rel="external">azelastine</a>, GC, or <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>. (See <a class="local">'Upper airway cough syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastroesophageal reflux</strong> – For patients with suspected cough due to gastroesophageal reflux, we suggest a trial of lifestyle modifications in combination with acid suppression medication (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Proton pump inhibitors appear to be more effective than H<sub>2</sub> antagonists in this setting. (See <a class="local">'Gastroesophageal reflux'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postinfectious cough</strong> – For patients with prolonged cough following an upper respiratory infection and clinical features suggestive of UACS, the treatment follows that for nonallergic UACS, as described above. (See <a class="local">'Persistent cough after upper respiratory tract infection'</a> above and <a class="local">'Upper airway cough syndrome'</a> above.)</p><p></p><p class="bulletIndent2">For patients with cough following an upper respiratory infection but few or no features of UACS, we treat bronchial hyperreactivity, as described above for cough variant asthma. (See <a class="local">'Persistent cough after upper respiratory tract infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Angiotensin-converting enzyme (ACE) inhibitor cough</strong> – For patients who develop a chronic cough while taking an ACE inhibitor, the ACE inhibitor should be discontinued as the first therapeutic approach. ACE-induced cough will usually resolve within a couple of weeks, although it will occasionally last up to four months. (See <a class="local">'Angiotensin-converting enzyme inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unexplained chronic cough</strong> – In some patients, the cause of chronic cough cannot be identified and empiric therapy for suspected causes has failed. For such patients, we suggest initial treatment with the nonopiate agent, <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a>, rather than using an opiate (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="9098" href="/z/d/drug information/9098.html" rel="external">Benzonatate</a> can be added if the cough persists despite dextromethorphan. Additionally, we suggest a therapeutic trial of multimodality speech therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Unexplained chronic cough'</a> above.)</p><p></p><p class="bulletIndent1">For patients whose cough does not respond to the above measures, we suggest a trial of the neuromodulators <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> rather than opiates or other agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Gabapentin and pregabalin are inhibitors of gamma aminobutyric acid release that are thought to reduce chronic cough via a central mechanism. Opiates also suppress cough centrally, with <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a> and <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> most commonly used for antitussive properties. Any of these centrally acting agents may have sedating adverse effects.</p><p></p><p class="bulletIndent1">When occasionally using opiates in patients whose cough is refractory to other measures, we typically prescribe a time-limited (eg, four- to six-week) course to facilitate mucosal healing while avoiding the risks associated with chronic therapy. Palliative opiates may also be useful in those with advanced interstitial lung diseases or malignancy. (See <a class="local">'Opiates'</a> above and  <a class="medical medical_review" href="/z/d/html/83242.html" rel="external">"Palliative care: Overview of cough, stridor, and hemoptysis in adults", section on 'Cough'</a>.)</p><p></p><p class="headingAnchor" id="H437034246"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ronald C Silvestri, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Irwin RS, French CL, Chang AB, et al. Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report. Chest 2018; 153:196.</a></li><li><a class="nounderline abstract_t">Iyer VN, Lim KG. Chronic cough: an update. Mayo Clin Proc 2013; 88:1115.</a></li><li><a class="nounderline abstract_t">De Vincentis A, Baldi F, Calderazzo M, et al. Chronic cough in adults: recommendations from an Italian intersociety consensus. Aging Clin Exp Res 2022; 34:1529.</a></li><li><a class="nounderline abstract_t">Gibson PG, Vertigan AE. Management of chronic refractory cough. BMJ 2015; 351:h5590.</a></li><li><a class="nounderline abstract_t">Moore A, Harnden A, Grant CC, et al. Clinically Diagnosing Pertussis-associated Cough in Adults and Children: CHEST Guideline and Expert Panel Report. Chest 2019; 155:147.</a></li><li><a class="nounderline abstract_t">Moore A, Ashdown HF, Shinkins B, et al. Clinical Characteristics of Pertussis-Associated Cough in Adults and Children: A Diagnostic Systematic Review and Meta-Analysis. Chest 2017; 152:353.</a></li><li><a class="nounderline abstract_t">Palombini BC, Villanova CA, Araújo E, et al. A pathogenic triad in chronic cough: asthma, postnasal drip syndrome, and gastroesophageal reflux disease. Chest 1999; 116:279.</a></li><li><a class="nounderline abstract_t">Côté A, Russell RJ, Boulet LP, et al. Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents: CHEST Guideline and Expert Panel Report. Chest 2020; 158:68.</a></li><li><a class="nounderline abstract_t">McGarvey LP, Heaney LG, Lawson JT, et al. Evaluation and outcome of patients with chronic non-productive cough using a comprehensive diagnostic protocol. Thorax 1998; 53:738.</a></li><li><a class="nounderline abstract_t">Lai K, Chen R, Lin J, et al. A prospective, multicenter survey on causes of chronic cough in China. Chest 2013; 143:613.</a></li><li><a class="nounderline abstract_t">Kahrilas PJ, Altman KW, Chang AB, et al. Chronic Cough Due to Gastroesophageal Reflux in Adults: CHEST Guideline and Expert Panel Report. Chest 2016; 150:1341.</a></li><li><a class="nounderline abstract_t">Chatkin JM, Ansarin K, Silkoff PE, et al. Exhaled nitric oxide as a noninvasive assessment of chronic cough. Am J Respir Crit Care Med 1999; 159:1810.</a></li><li><a class="nounderline abstract_t">Song WJ, Kim HJ, Shim JS, et al. Diagnostic accuracy of fractional exhaled nitric oxide measurement in predicting cough-variant asthma and eosinophilic bronchitis in adults with chronic cough: A systematic review and meta-analysis. J Allergy Clin Immunol 2017; 140:701.</a></li><li><a class="nounderline abstract_t">Khatri SB, Iaccarino JM, Barochia A, et al. Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2021; 204:e97.</a></li><li><a class="nounderline abstract_t">Birring SS. Controversies in the evaluation and management of chronic cough. Am J Respir Crit Care Med 2011; 183:708.</a></li><li><a class="nounderline abstract_t">Cheriyan S, Greenberger PA, Patterson R. Outcome of cough variant asthma treated with inhaled steroids. Ann Allergy 1994; 73:478.</a></li><li><a class="nounderline abstract_t">Spector SL, Tan RA. Effectiveness of montelukast in the treatment of cough variant asthma. Ann Allergy Asthma Immunol 2004; 93:232.</a></li><li><a class="nounderline abstract_t">Dicpinigaitis PV, Dobkin JB, Reichel J. Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. J Asthma 2002; 39:291.</a></li><li><a class="nounderline abstract_t">Dicpinigaitis PV. Chronic cough due to asthma: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:75S.</a></li><li><a class="nounderline abstract_t">Brightling CE, Ward R, Goh KL, et al. Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med 1999; 160:406.</a></li><li><a class="nounderline abstract_t">Niimi A. Narrative Review: how long should patients with cough variant asthma or non-asthmatic eosinophilic bronchitis be treated? J Thorac Dis 2021; 13:3197.</a></li><li><a class="nounderline abstract_t">Lemière C, Efthimiadis A, Hargreave FE. Occupational eosinophilic bronchitis without asthma: an unknown occupational airway disease. J Allergy Clin Immunol 1997; 100:852.</a></li><li><a class="nounderline abstract_t">Di Stefano F, Di Giampaolo L, Verna N, Di Gioacchino M. Occupational eosinophilic bronchitis in a foundry worker exposed to isocyanate and a baker exposed to flour. Thorax 2007; 62:368.</a></li><li><a class="nounderline abstract_t">Maniscalco M, Faraone S, Sofia M, et al. Extended analysis of exhaled and nasal nitric oxide for the evaluation of chronic cough. Respir Med 2015; 109:970.</a></li><li><a class="nounderline abstract_t">Oh MJ, Lee JY, Lee BJ, Choi DC. Exhaled nitric oxide measurement is useful for the exclusion of nonasthmatic eosinophilic bronchitis in patients with chronic cough. Chest 2008; 134:990.</a></li><li><a class="nounderline abstract_t">Brightling CE. Chronic cough due to nonasthmatic eosinophilic bronchitis: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:116S.</a></li><li><a class="nounderline abstract_t">Brightling CE, Ward R, Wardlaw AJ, Pavord ID. Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis. Eur Respir J 2000; 15:682.</a></li><li><a class="nounderline abstract_t">Zhan W, Tang J, Chen X, et al. Duration of treatment with inhaled corticosteroids in nonasthmatic eosinophilic bronchitis: a randomized open label trial. Ther Adv Respir Dis 2019; 13:1753466619891520.</a></li><li><a class="nounderline abstract_t">Cai C, He MZ, Zhong SQ, et al. Add-on montelukast vs double-dose budesonide in nonasthmatic eosinophilic bronchitis: a pilot study. Respir Med 2012; 106:1369.</a></li><li><a class="nounderline abstract_t">Bao W, Liu P, Qiu Z, et al. Efficacy of add-on montelukast in nonasthmatic eosinophilic bronchitis: the additive effect on airway inflammation, cough and life quality. Chin Med J (Engl) 2015; 128:39.</a></li><li><a class="nounderline abstract_t">Johnstone KJ, Chang AB, Fong KM, et al. Inhaled corticosteroids for subacute and chronic cough in adults. Cochrane Database Syst Rev 2013; :CD009305.</a></li><li><a class="nounderline abstract_t">Ribeiro M, Pereira CA, Nery LE, et al. High-dose inhaled beclomethasone treatment in patients with chronic cough: a randomized placebo-controlled study. Ann Allergy Asthma Immunol 2007; 99:61.</a></li><li><a class="nounderline abstract_t">Boulet LP, Milot J, Boutet M, et al. Airway inflammation in nonasthmatic subjects with chronic cough. Am J Respir Crit Care Med 1994; 149:482.</a></li><li><a class="nounderline abstract_t">Evald T, Munch EP, Kok-Jensen A. Chronic non-asthmatic cough is not affected by inhaled beclomethasone dipropionate. A controlled double blind clinical trial. Allergy 1989; 44:510.</a></li><li><a class="nounderline abstract_t">Pratter MR. Chronic upper airway cough syndrome secondary to rhinosinus diseases (previously referred to as postnasal drip syndrome): ACCP evidence-based clinical practice guidelines. Chest 2006; 129:63S.</a></li><li><a class="nounderline abstract_t">Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol 2020; 146:721.</a></li><li><a class="nounderline abstract_t">Irwin RS, Madison JM. The diagnosis and treatment of cough. N Engl J Med 2000; 343:1715.</a></li><li><a class="nounderline abstract_t">Lee JH, Lee JW, An J, et al. Efficacy of non-sedating H1-receptor antihistamines in adults and adolescents with chronic cough: A systematic review. World Allergy Organ J 2021; 14:100568.</a></li><li><a class="nounderline abstract_t">Grossman J, Banov C, Boggs P, et al. Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications. J Allergy Clin Immunol 1995; 95:1123.</a></li><li><a class="nounderline abstract_t">Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis 1990; 141:640.</a></li><li><a class="nounderline abstract_t">Irwin RS, French CL, Curley FJ, et al. Chronic cough due to gastroesophageal reflux. Clinical, diagnostic, and pathogenetic aspects. Chest 1993; 104:1511.</a></li><li><a class="nounderline abstract_t">Poe RH, Kallay MC. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. Chest 2003; 123:679.</a></li><li><a class="nounderline abstract_t">Chang AB, Lasserson TJ, Gaffney J, et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2011; :CD004823.</a></li><li><a class="nounderline abstract_t">Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135:1383.</a></li><li><a class="nounderline abstract_t">Allen CJ, Anvari M. Gastro-oesophageal reflux related cough and its response to laparoscopic fundoplication. Thorax 1998; 53:963.</a></li><li><a class="nounderline abstract_t">Hoppo T, Komatsu Y, Jobe BA. Antireflux surgery in patients with chronic cough and abnormal proximal exposure as measured by hypopharyngeal multichannel intraluminal impedance. JAMA Surg 2013; 148:608.</a></li><li><a class="nounderline abstract_t">Iqbal M, Batch AJ, Spychal RT, Cooper BT. Outcome of surgical fundoplication for extraesophageal (atypical) manifestations of gastroesophageal reflux disease in adults: a systematic review. J Laparoendosc Adv Surg Tech A 2008; 18:789.</a></li><li><a class="nounderline abstract_t">Tustumi F, Bernardo WM, Mariano da Rocha JR, et al. Anti-reflux surgery for controlling respiratory symptoms of gastro-esophageal reflux disease: A systematic review and meta-analysis. Asian J Surg 2021; 44:2.</a></li><li><a class="nounderline abstract_t">Park A, Weltz AS, Sanford Z, et al. Laparoscopic antireflux surgery (LARS) is highly effective in the treatment of select patients with chronic cough. Surgery 2019; 166:34.</a></li><li><a class="nounderline abstract_t">Dowgiałło-Gornowicz N, Masiewicz A, Kacperczyk J, et al. Long-Term Outcomes of Chronic Cough Reduction after Laparoscopic Nissen Fundoplication-A Single-Center Study. Medicina (Kaunas) 2021; 58.</a></li><li><a class="nounderline abstract_t">Pratter MR. Cough and the common cold: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:72S.</a></li><li><a class="nounderline abstract_t">Curley FJ, Irwin RS, Pratter MR, et al. Cough and the common cold. Am Rev Respir Dis 1988; 138:305.</a></li><li><a class="nounderline abstract_t">Berkowitz RB, Tinkelman DG. Evaluation of oral terfenadine for treatment of the common cold. Ann Allergy 1991; 67:593.</a></li><li><a class="nounderline abstract_t">Berkowitz RB, Connell JT, Dietz AJ, et al. The effectiveness of the nonsedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Ann Allergy 1989; 63:336.</a></li><li><a class="nounderline abstract_t">Braman SS. Postinfectious cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:138S.</a></li><li><a class="nounderline abstract_t">Holmes PW, Barter CE, Pierce RJ. Chronic persistent cough: use of ipratropium bromide in undiagnosed cases following upper respiratory tract infection. Respir Med 1992; 86:425.</a></li><li><a class="nounderline abstract_t">Senzilet LD, Halperin SA, Spika JS, et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis 2001; 32:1691.</a></li><li><a class="nounderline abstract_t">Wang K, Bettiol S, Thompson MJ, et al. Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst Rev 2014; :CD003257.</a></li><li><a class="nounderline abstract_t">Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:169S.</a></li><li><a class="nounderline abstract_t">Lacourcière Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. J Hypertens 1994; 12:1387.</a></li><li><a class="nounderline abstract_t">Tanaka H, Teramoto S, Oashi K, et al. Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation 2001; 104:281.</a></li><li><a class="nounderline abstract_t">Gibson P, Wang G, McGarvey L, et al. Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report. Chest 2016; 149:27.</a></li><li><a class="nounderline abstract_t">Woodcock A, Young EC, Smith JA. New insights in cough. Br Med Bull 2010; 96:61.</a></li><li><a class="nounderline abstract_t">Haque RA, Usmani OS, Barnes PJ. Chronic idiopathic cough: a discrete clinical entity? Chest 2005; 127:1710.</a></li><li><a class="nounderline abstract_t">Morice AH. The cough hypersensitivity syndrome: a novel paradigm for understanding cough. Lung 2010; 188 Suppl 1:S87.</a></li><li><a class="nounderline abstract_t">Mitchell JE, Campbell AP, New NE, et al. Expression and characterization of the intracellular vanilloid receptor (TRPV1) in bronchi from patients with chronic cough. Exp Lung Res 2005; 31:295.</a></li><li><a class="nounderline abstract_t">Adcock JJ. TRPV1 receptors in sensitisation of cough and pain reflexes. Pulm Pharmacol Ther 2009; 22:65.</a></li><li><a class="nounderline abstract_t">Grace MS, Belvisi MG. TRPA1 receptors in cough. Pulm Pharmacol Ther 2011; 24:286.</a></li><li><a class="nounderline abstract_t">Chung KF, McGarvey L, Song WJ, et al. Cough hypersensitivity and chronic cough. Nat Rev Dis Primers 2022; 8:45.</a></li><li><a class="nounderline abstract_t">Irwin RS, Curley FJ. The treatment of cough. A comprehensive review. Chest 1991; 99:1477.</a></li><li><a class="nounderline abstract_t">Belvisi MG, Geppetti P. Cough. 7: Current and future drugs for the treatment of chronic cough. Thorax 2004; 59:438.</a></li><li><a class="nounderline abstract_t">Irwin RS, Curley FJ, Bennett FM. Appropriate use of antitussives and protussives. A practical review. Drugs 1993; 46:80.</a></li><li><a class="nounderline abstract_t">Bolser DC. Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:238S.</a></li><li><a class="nounderline abstract_t">Vertigan AE, Kapela SL, Ryan NM, et al. Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial. Chest 2016; 149:639.</a></li><li><a class="nounderline abstract_t">Gibson PG, Vertigan AE. Speech pathology for chronic cough: a new approach. Pulm Pharmacol Ther 2009; 22:159.</a></li><li><a class="nounderline abstract_t">Chamberlain S, Birring SS, Garrod R. Nonpharmacological interventions for refractory chronic cough patients: systematic review. Lung 2014; 192:75.</a></li><li><a class="nounderline abstract_t">Slovarp LJ, Reynolds JE, Tolbert S, et al. Cough desensitization treatment for patients with refractory chronic cough: results of a second pilot randomized control trial. BMC Pulm Med 2023; 23:148.</a></li><li><a class="nounderline abstract_t">Yancy WS Jr, McCrory DC, Coeytaux RR, et al. Efficacy and tolerability of treatments for chronic cough: a systematic review and meta-analysis. Chest 2013; 144:1827.</a></li><li><a class="nounderline abstract_t">Matthys H, Bleicher B, Bleicher U. Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough. J Int Med Res 1983; 11:92.</a></li><li><a class="nounderline abstract_t">Aylward M, Maddock J, Davies DE, et al. Dextromethorphan and codeine: comparison of plasma kinetics and antitussive effects. Eur J Respir Dis 1984; 65:283.</a></li><li><a class="nounderline abstract_t">Dicpinigaitis PV, Gayle YE, Solomon G, Gilbert RD. Inhibition of cough-reflex sensitivity by benzonatate and guaifenesin in acute viral cough. Respir Med 2009; 103:902.</a></li><li><a class="nounderline abstract_t">Doona M, Walsh D. Benzonatate for opioid-resistant cough in advanced cancer. Palliat Med 1998; 12:55.</a></li><li><a class="nounderline abstract_t">McLawhorn MW, Goulding MR, Gill RK, Michele TM. Analysis of benzonatate overdoses among adults and children from 1969-2010 by the United States Food and Drug Administration. Pharmacotherapy 2013; 33:38.</a></li><li><a class="nounderline abstract_t">Lim KG, Rank MA, Hahn PY, et al. Long-term safety of nebulized lidocaine for adults with difficult-to-control chronic cough: a case series. Chest 2013; 143:1060.</a></li><li><a class="nounderline abstract_t">Ryan NM. A review on the efficacy and safety of gabapentin in the treatment of chronic cough. Expert Opin Pharmacother 2015; 16:135.</a></li><li><a class="nounderline abstract_t">Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380:1583.</a></li><li><a class="nounderline abstract_t">Morice AH, Menon MS, Mulrennan SA, et al. Opiate therapy in chronic cough. Am J Respir Crit Care Med 2007; 175:312.</a></li><li><a class="nounderline abstract_t">Smith J, Owen E, Earis J, Woodcock A. Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2006; 117:831.</a></li><li><a class="nounderline abstract_t">Woodcock A, McLeod RL, Sadeh J, Smith JA. The efficacy of a NOP1 agonist (SCH486757) in subacute cough. Lung 2010; 188 Suppl 1:S47.</a></li><li><a class="nounderline abstract_t">Chung KF. Currently available cough suppressants for chronic cough. Lung 2008; 186 Suppl 1:S82.</a></li><li><a class="nounderline abstract_t">Zhang M, Sykes DL, Sadofsky LR, Morice AH. ATP, an attractive target for the treatment of refractory chronic cough. Purinergic Signal 2022; 18:289.</a></li><li><a class="nounderline abstract_t">Abdulqawi R, Dockry R, Holt K, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2015; 385:1198.</a></li><li><a class="nounderline abstract_t">McGarvey LP, Birring SS, Morice AH, et al. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet 2022; 399:909.</a></li><li><a class="nounderline abstract_t">Sykes DL, Zhang M, Morice AH. Treatment of chronic cough: P2X3 receptor antagonists and beyond. Pharmacol Ther 2022; 237:108166.</a></li><li><a class="nounderline abstract_t">Ford AP, Dillon MP, Kitt MM, Gever JR. The discovery and development of gefapixant. Auton Neurosci 2021; 235:102859.</a></li><li><a class="nounderline abstract_t">Kum E, Patel M, Diab N, et al. Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis. JAMA 2023; 330:1359.</a></li><li><a class="nounderline abstract_t">Niimi A, Saito J, Kamei T, et al. Randomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic cough. Eur Respir J 2022; 59.</a></li><li><a class="nounderline abstract_t">Hodgson D, Anderson J, Reynolds C, et al. The Effects of Azithromycin in Treatment-Resistant Cough: A Randomized, Double-Blind, Placebo-Controlled Trial. Chest 2016; 149:1052.</a></li><li><a class="nounderline abstract_t">Yousaf N, Monteiro W, Parker D, et al. Long-term low-dose erythromycin in patients with unexplained chronic cough: a double-blind placebo controlled trial. Thorax 2010; 65:1107.</a></li><li class="breakAll">Comroe JH Jr. Special acts involving breathing. In: Physiology of Respiration: An Introductory Text, 2nd ed, Year Book Medical Publishers, Chicago 1974. p.230.</li><li><a class="nounderline abstract_t">Irwin RS, Baumann MH, Bolser DC, et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:1S.</a></li><li><a class="nounderline abstract_t">Smyrnios NA, Irwin RS, Curley FJ, French CL. From a prospective study of chronic cough: diagnostic and therapeutic aspects in older adults. Arch Intern Med 1998; 158:1222.</a></li><li><a class="nounderline abstract_t">Hanak V, Hartman TE, Ryu JH. Cough-induced rib fractures. Mayo Clin Proc 2005; 80:879.</a></li></ol></div><div id="topicVersionRevision">Topic 1428 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31515408" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ERS guidelines on the diagnosis and treatment of chronic cough in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29080708" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24079681" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chronic cough: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35666453" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Chronic cough in adults: recommendations from an Italian intersociety consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26666537" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of chronic refractory cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30321509" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinically Diagnosing Pertussis-associated Cough in Adults and Children: CHEST Guideline and Expert Panel Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28511929" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical Characteristics of Pertussis-Associated Cough in Adults and Children: A Diagnostic Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10453852" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A pathogenic triad in chronic cough: asthma, postnasal drip syndrome, and gastroesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31972181" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents: CHEST Guideline and Expert Panel Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10319055" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Evaluation and outcome of patients with chronic non-productive cough using a comprehensive diagnostic protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23238526" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A prospective, multicenter survey on causes of chronic cough in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27614002" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chronic Cough Due to Gastroesophageal Reflux in Adults: CHEST Guideline and Expert Panel Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10351923" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Exhaled nitric oxide as a noninvasive assessment of chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28088474" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diagnostic accuracy of fractional exhaled nitric oxide measurement in predicting cough-variant asthma and eosinophilic bronchitis in adults with chronic cough: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34779751" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21148722" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Controversies in the evaluation and management of chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7998659" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Outcome of cough variant asthma treated with inhaled steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15478381" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effectiveness of montelukast in the treatment of cough variant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12095178" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16428696" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Chronic cough due to asthma: ACCP evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430705" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Eosinophilic bronchitis is an important cause of chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34164212" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Narrative Review: how long should patients with cough variant asthma or non-asthmatic eosinophilic bronchitis be treated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9438499" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Occupational eosinophilic bronchitis without asthma: an unknown occupational airway disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16055615" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Occupational eosinophilic bronchitis in a foundry worker exposed to isocyanate and a baker exposed to flour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26048083" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Extended analysis of exhaled and nasal nitric oxide for the evaluation of chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18583518" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Exhaled nitric oxide measurement is useful for the exclusion of nonasthmatic eosinophilic bronchitis in patients with chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16428700" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Chronic cough due to nonasthmatic eosinophilic bronchitis: ACCP evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10780759" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31847717" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Duration of treatment with inhaled corticosteroids in nonasthmatic eosinophilic bronchitis: a randomized open label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22819521" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Add-on montelukast vs double-dose budesonide in nonasthmatic eosinophilic bronchitis: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25563311" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Efficacy of add-on montelukast in nonasthmatic eosinophilic bronchitis: the additive effect on airway inflammation, cough and life quality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543575" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Inhaled corticosteroids for subacute and chronic cough in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17650832" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High-dose inhaled beclomethasone treatment in patients with chronic cough: a randomized placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8306050" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Airway inflammation in nonasthmatic subjects with chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2683836" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Chronic non-asthmatic cough is not affected by inhaled beclomethasone dipropionate. A controlled double blind clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16428694" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Chronic upper airway cough syndrome secondary to rhinosinus diseases (previously referred to as postnasal drip syndrome): ACCP evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32707227" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Rhinitis 2020: A practice parameter update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11106722" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The diagnosis and treatment of cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34386152" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy of non-sedating H1-receptor antihistamines in adults and adolescents with chronic cough: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7538520" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2178528" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8222816" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Chronic cough due to gastroesophageal reflux. Clinical, diagnostic, and pathogenetic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12628862" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21249664" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18789939" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10193396" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Gastro-oesophageal reflux related cough and its response to laparoscopic fundoplication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23700139" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Antireflux surgery in patients with chronic cough and abnormal proximal exposure as measured by hypopharyngeal multichannel intraluminal impedance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19105666" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Outcome of surgical fundoplication for extraesophageal (atypical) manifestations of gastroesophageal reflux disease in adults: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32534727" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Anti-reflux surgery for controlling respiratory symptoms of gastro-esophageal reflux disease: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30955850" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Laparoscopic antireflux surgery (LARS) is highly effective in the treatment of select patients with chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35056354" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Long-Term Outcomes of Chronic Cough Reduction after Laparoscopic Nissen Fundoplication-A Single-Center Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16428695" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cough and the common cold: ACCP evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3057962" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cough and the common cold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1750722" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Evaluation of oral terfenadine for treatment of the common cold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2529799" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The effectiveness of the nonsedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16428703" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Postinfectious cough: ACCP evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1462022" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Chronic persistent cough: use of ipratropium bromide in undiagnosed cases following upper respiratory tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11360208" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pertussis is a frequent cause of prolonged cough illness in adults and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25243777" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Symptomatic treatment of the cough in whooping cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16428706" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7706699" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11457745" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26426314" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21030396" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : New insights in cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888850" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Chronic idiopathic cough: a discrete clinical entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19809853" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The cough hypersensitivity syndrome: a novel paradigm for understanding cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15962710" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Expression and characterization of the intracellular vanilloid receptor (TRPV1) in bronchi from patients with chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19141328" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : TRPV1 receptors in sensitisation of cough and pain reflexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21074632" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : TRPA1 receptors in cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35773287" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cough hypersensitivity and chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2036833" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The treatment of cough. A comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15115877" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cough. 7: Current and future drugs for the treatment of chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7691510" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Appropriate use of antitussives and protussives. A practical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16428717" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26447687" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19061964" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Speech pathology for chronic cough: a new approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24121952" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Nonpharmacological interventions for refractory chronic cough patients: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37118696" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cough desensitization treatment for patients with refractory chronic cough: results of a second pilot randomized control trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23928798" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Efficacy and tolerability of treatments for chronic cough: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6852361" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6539224" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Dextromethorphan and codeine: comparison of plasma kinetics and antitussive effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19121573" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Inhibition of cough-reflex sensitivity by benzonatate and guaifenesin in acute viral cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9616460" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Benzonatate for opioid-resistant cough in advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23307543" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Analysis of benzonatate overdoses among adults and children from 1969-2010 by the United States Food and Drug Administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23238692" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Long-term safety of nebulized lidocaine for adults with difficult-to-control chronic cough: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25380977" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A review on the efficacy and safety of gabapentin in the treatment of chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22951084" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17122382" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Opiate therapy in chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16630941" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19937046" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The efficacy of a NOP1 agonist (SCH486757) in subacute cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17909897" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Currently available cough suppressants for chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35727480" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : ATP, an attractive target for the treatment of refractory chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25467586" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35248186" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35263649" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Treatment of chronic cough: P2X3 receptor antagonists and beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34403981" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The discovery and development of gefapixant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37694849" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34649978" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Randomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26836927" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The Effects of Azithromycin in Treatment-Resistant Cough: A Randomized, Double-Blind, Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20965928" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Long-term low-dose erythromycin in patients with unexplained chronic cough: a double-blind placebo controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20965928" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Long-term low-dose erythromycin in patients with unexplained chronic cough: a double-blind placebo controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16428686" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9625401" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : From a prospective study of chronic cough: diagnostic and therapeutic aspects in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16007893" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Cough-induced rib fractures.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
